NBIA News and EventsNews, current and past events
News
SAVE THE DATE: October, 17-19, 2024 - 9th International symposium on NBIA, Istanbul, Turkey
More information is available here: https://istanbulnbiasymposium.com/
In the past
October, 13-15, 2022 - International symposium on NBIA & related disorders
The 8th International Symposium on Neurodegeneration with Brain Iron Accumulation & Related Disorders will take place between October 13th and 15th in Lausanne, Switzerland. More information is available here:
https://nbiasuisse.org/8th-international-symposium-on-nbia/
February 22, 2021 The article about Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) is now officially published and is availalbe under this link https://doi.org/10.3389/fneur.2021.642228
Postponed: October, 1-3, 2020, 7th International Symposium on NBIA - Lausanne, Switzerland
Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
For further information, please read the press release. The statement of the principle investigator Prof. Thomas Klopstock's (in German) can be found here.
July 22, 2019, NBIA Patient registry is progressing successfully
July 01, 2019 Results from Phase 3 TIRCON Study of Deferiprone in Patients with PKAN
...have been published in Lancet Neurology, the publication abstract is available here.
April, 7-8, 2017, 6th International Symposium on NBIA
The 6th International Symposium on Neurodegeneration with Brain Iron Accumulation & Related Disorders took place on April 7th and 8th in Stevenson, Washington, USA. For more information, please visit http://bit.ly/NBIASymposium.
June 17, 2016, Orphan drug designation granted
The European Medicines Agency (EMA) has granted orphan drug designation to a new candidate compound CAB1803 for the treatment of PKAN, developed by TIRCON partners Acies Bio and University Medical Centre Groningen. For further information, please read the press release.
March 9, 2015, Clinical trial fully randomized
The Clinical trial of Deferiprone in PKAN is now fully randomized.
December 11, 2013, A TIRCON patent has recently been filed
TIRCON partners UMCG and Acies Bio developed a new candidate compound for the treatment of PKAN. For further information, please read the press release.
